UNCONVENTIONAL PATTERN OF RESPONSE IN A METASTATIC MELANOMA PATIENT TREATED WITH IPILIMUMAB

0
We present the case of a 74 year old man who achieved a complete response for hepatic and cutaneous metastasis and stabilization of his lymph node metastases after treatment with ipilimumab at 10 mg/Kg.
The patient was diagnosed with right foot cutaneous melanoma in February 2004.
In October the patient became metastatic and he underwent three different lines of tradi-tional chemotherapy (Fotemustine, Dacarbazin and Carboplatin with Thalidomide) but each time a progression of the disease was noted. Consequently, the patient was enrolled in Protocol CA180008 and treated with ipilimumab 10mg/Kg every 3 weeks for 4 cycles.
Ipilimumab has been established as a drug able to induce long-lasting responses, and has been approved for patients with metastatic melanoma in first- and second-line treatment by the FDA and in second-line treatment by the EMA.
Share.

Leave A Reply